Kazia Therapeutics (KZIA) Common Equity (2017 - 2025)

Kazia Therapeutics' Common Equity history spans 6 years, with the latest figure at -$5.3 million for Q2 2025.

  • For Q2 2025, Common Equity rose 19.47% year-over-year to -$5.3 million; the TTM value through Jun 2025 reached -$5.3 million, up 19.47%, while the annual FY2025 figure was -$5.3 million, 19.47% up from the prior year.
  • Common Equity reached -$5.3 million in Q2 2025 per KZIA's latest filing, up from -$6.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $13.1 million in Q2 2022 to a low of -$6.6 million in Q2 2024.
  • Average Common Equity over 4 years is $2.3 million, with a median of $1.4 million recorded in 2023.
  • Peak YoY movement for Common Equity: tumbled 181.97% in 2024, then rose 19.47% in 2025.
  • A 4-year view of Common Equity shows it stood at $13.1 million in 2022, then crashed by 38.47% to $8.1 million in 2023, then crashed by 181.97% to -$6.6 million in 2024, then grew by 19.47% to -$5.3 million in 2025.
  • Per Business Quant, the three most recent readings for KZIA's Common Equity are -$5.3 million (Q2 2025), -$6.6 million (Q2 2024), and $8.1 million (Q2 2023).